Latest news
Lilly beats forecasts as Mounjaro, Zepbound drive 48% revenue surge - The Pharma LetterThe Pharma Letter · Thu, 06 Aug 2026 11:50:30 GMTLilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo - 933thedrive.com933thedrive.com · Thu, 06 Aug 2026 04:36:48 GMTEli Lilly’s Obesity Drugs Drive Massive Revenue Growth - ForbesForbes · Wed, 05 Aug 2026 21:00:36 GMTNovo CEO looks to speed up R&D as share drop shows gap with Lilly - 933thedrive.com933thedrive.com · Wed, 05 Aug 2026 08:30:44 GMTEli Lilly to offer early access to next-gen obesity drug to some patients - 933thedrive.com933thedrive.com · Mon, 03 Aug 2026 22:51:27 GMTWill Mounjaro & Zepbound Drive Lilly's Q2 Results: Buy, Sell or Hold? - Yahoo FinanceYahoo Finance · Mon, 03 Aug 2026 15:17:00 GMTLilly, Resilience to invest $750 million in US drug manufacturing expansion - 933thedrive.com933thedrive.com · Thu, 30 Jul 2026 07:00:00 GMT